Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDHB | P21912 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442659 | 0.86 | PTGDR2 (0.52) | SDHBALDH1A1SMN1; SMN2MKNK1MKNK2 | |
| SCHEMBL5197304 | 0.84 | MAPT (0.49) | SDHBALDH1A1TP53SMN1; SMN2MKNK1 | |
| SCHEMBL5444680 | 0.82 | SDHB (0.57) | SDHBALDH1A1TP53SMN1; SMN2HSP90AA1 | |
| SCHEMBL5441383 | 0.81 | MAPT (0.57) | ALDH1A1TP53SMN1; SMN2MKNK1MKNK2 | |
| SCHEMBL5440937 | 0.80 | MAPT (0.50) | SDHBSMN1; SMN2MKNK1MKNK2PTGDR2 | |
| SCHEMBL5444851 | 0.77 | SDHB (0.52) | SDHBALDH1A1TP53HSP90AA1HSP90AB1 | |
| SCHEMBL5439738 | 0.76 | MAPT (0.45) | SDHBALDH1A1TP53SMN1; SMN2MKNK1 | |
| SCHEMBL5433988 | 0.76 | SDHB (0.43) | SDHBSMN1; SMN2MKNK1MKNK2PTGDR2 | |
| SCHEMBL5443008 | 0.75 | SDHB (0.49) | SDHBTP53 | |
| SCHEMBL6116487 | 0.74 | ALDH1A1 (0.65) | SDHBALDH1A1TP53SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | SDHB 1074/4885ALDH1A1 3403/4885TP53 4883/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | SDHB 1134/4885ALDH1A1 2717/4885TP53 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.